Final results of MONALESSA‐2 demonstrated a great OS benefit for the cyclin dependent kinase (CDK)4/6 inhibitor ribociclib plus endocrine therapy as first-line treatment of patients with hormone receptor (HR)-positive, Her2-negative breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.